In this article, Andrew Butcher writes about the importance of stakeholder engagement as effective but high-cost new therapies have potentially damaging financial implications for the healthcare systems expected to fund them. Regrettably, the pharmaceutical industry is often identified as the cause of the problems rather than the key players in solving them.
CRA leading the way in analytics
In recent years, the adoption of advanced treatments in inflammatory bowel disease has evolved. Oral products have captured a significant share in ulcerative...